Success of innovative mental health research leads to exceptional additional support for new project from IMI, world’s biggest public-industry drug development partnership

Press/Media: Research › Academic

Description

Building on the success of innovative research by the PRISM project, the Innovative Medicine Initiative 2, a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has backed the program with funding for a new project to explore the underlying biology of Alzheimer’s disease, schizophrenia and Major Depressive Disorder (MDD). The new PRISM 2 (Psychiatric Ratings using Intermediate Stratified Markers 2) project aims to identify quantitative biological features common across the diseases, opening the possibility of developing targeted treatments irrespective of traditional diagnosis.

Period22-Jun-2021 → 28-Jul-2021

Media coverage

3

Media coverage

  • TitlePRISM 2 to build on PRISM’s ground-breaking social withdrawal work
    Degree of recognitionInternational
    Media name/outletIMI
    Media typeWeb
    Country/TerritoryNetherlands
    Date28/07/2021
    DescriptionIMI’s PRISM project shed new light on social withdrawal, a common early symptom of many neurological disorders. Now PRISM 2 is set to build on its results.
    Producer/AuthorIMI press release
    URLhttps://www.imi.europa.eu/news-events/newsroom/prism-2-build-prisms-ground-breaking-social-withdrawal-work
    PersonsMartien Kas
  • TitleNew project aims to identify quantitative biological features common across diseases
    Degree of recognitionInternational
    Media name/outletNews-Medical.Net
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date23/06/2021
    DescriptionBuilding on the success of innovative research by the PRISM project, the Innovative Medicine Initiative 2, a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has backed the program with funding for a new project to explore the underlying biology of Alzheimer's disease, schizophrenia and Major Depressive Disorder (MDD).
    Producer/AuthorEmily Henderson
    URLhttps://www.news-medical.net/news/20210623/New-project-aims-to-identify-quantitative-biological-features-common-across-diseases.aspx
    PersonsMartien Kas
  • TitleSuccess of innovative mental health research leads to exceptional additional support for new project from IMI, World’s biggest public-industry drug development partnership
    Degree of recognitionInternational
    Media name/outletAlphaGalileo
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date22/06/2021
    DescriptionBuilding on the success of innovative research by the PRISM project, the Innovative Medicine Initiative 2, a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has backed the program with funding for a new project to explore the underlying biology of Alzheimer’s disease, schizophrenia and Major Depressive Disorder (MDD). The new PRISM 2 (Psychiatric Ratings using Intermediate Stratified Markers 2) project aims to identify quantitative biological features common across the diseases, opening the possibility of developing targeted treatments irrespective of traditional diagnosis.
    Producer/AuthorPRISM
    URLhttps://www.alphagalileo.org/en-gb/Item-Display/ItemId/209716
    PersonsMartien Kas
View all 3
View less

Related content